Topic
fda-clearance
2 stories related to this topic, newest first.
forbes.comscience14 days agoDeveloping
NRx Pharmaceuticals to Report First-Quarter Earnings on May 18
Analysts expect NRx Pharmaceuticals to post a loss of 11 cents per share on $19.43 million in revenue. The company recently received FDA clearance to begin a clinical trial of NRX-101. Several analysts maintained Buy ratings with price targets ranging from $25 to $49.
Benzingafinance14 days agoDeveloping
Elutia Reports $3.1 Million in Q1 2026 Net Sales, Up 6% Year-over-Year
Elutia released first-quarter results on May 14, 2026, showing improved gross margin and progress on its automated manufacturing platform. The company anticipates FDA clearance for its NXT41 product in Q4 2026. CEO Randy Mills highlighted the $1.5 billion U.S. breast reconstructi…